Anastasia Ganina

Mrs. Anastasia Ganina

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AGAnastasia Ganina
Anastasia Ganina
MAManarbek Askarov
Manarbek Askarov
LKLarissa Kozina
Larissa Kozina
MKMadina Karimova
Madina Karimova
YSYerzhan Shayakhmetov
Yerzhan Shayakhmetov
ABAbay Baigenzhin
Abay Baigenzhin
This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.

11 December 2025 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
ABAbay Baigenzhin
Abay Baigenzhin
ECElmira Chuvakova
Elmira Chuvakova
AZAigerim Zhakupova
Aigerim Zhakupova
AAAizhan Akhayeva
Aizhan Akhayeva
AGAnastasia Ganina
Anastasia Ganina
During the last decade, clinical application of extracellular vesicles (EVs) is of growing interest. Despite the progress in exploring the therapeutic potential of EVs, e.g. as disease markers or the carriers for therapeutic substances, it is important to identify proper storage conditions – this issue is indeed challenging. A subtype of EVs known as exosomes is of great importance in the therapeutic applications because they participate in the regulation of intercellular communication. Currently, exosomes are considered as a promising tool in the regenerative medicine. The therapeutic potential of exosomes and other subtypes of EVs, especially for their using in immunomodulation and drug delivery, dictates great attention to the methods for their storage, in particular for a long periods of time. Lyophilization is one of the best such methods designed to preserve cell-free EV-based products. In our mini-review, we discuss the main methods developed for stabilizing cell-free products and getting stable solid forms of EVs that are capable for long-term storage. We also point out that the methods need to be following both the ease of transportation and the retaining the functionally important properties for in vivo applications. The development of optimal protocols for storing the EVs are therefore crucially important for warranting that structural and functional integrity of EVs, exosomes in particular, are maintained intact or at least modified as less as possible. For comprehensiveness of our review, we refer to original studies which investigated how the storage temperature and freezing methods may affect stability of the final EV product. We summarize advances in the area of freeze-drying EVs (exosomes), the selection of optimal process parameters and lyoprotectants, the interplay between lyophilization parameters and specific functional properties of exosomes, and the preservation of their biological activity after reconstitution before application in vivo.

Verified
Journal Article
Open access
PDF file
AOAliya Orassay
Aliya Orassay
NYNaizabek Yerzhigit
Naizabek Yerzhigit
AGAnastasia Ganina
Anastasia Ganina
ECElmira Chuvakova
Elmira Chuvakova
OLOleg Lookin
Oleg Lookin
ABAbay Baigenzhin
Abay Baigenzhin
Traditional treatments of autoimmune diseases relying on systemic immunosuppression often lack curative potential and have severe side effects. Mesenchymal stem cells (MSCs) are a promising alternative due to their immunomodulatory properties; however, whole-cell therapies have certain limitations. MSC-derived extracellular vesicles (EVs), including small vesicles—exosomes—have emerged as a safe cell-free therapeutic platform capable of crossing biological barriers and delivering bioactive cargo with low immunogenicity. Various types of RNAs abundantly produced by host MSCs represent a key element of EV content. In particular, EVs carry small RNAs, which essentially determine cellular life and fate. Our review provides a comprehensive mechanistic framework for the use of RNA-loaded EVs, specifically those carrying microRNAs (miRNAs), small interfering RNAs (siRNAs), and messenger RNAs (mRNAs), in restoring immune homeostasis. We detail the biogenesis and molecular mechanisms governing sorting of RNA into EVs, along with endogenous and exogenous engineering strategies to enhance therapeutic potency. We examine how RNA-loaded EVs modulate immunological processes like reprogramming of macrophage M1-M2 polarization, Th17/Treg balance, and suppression of inflammatory signaling pathways such as NF-κB and the NLRP3 inflammasome. We address critical translational challenges—EV heterogeneity, manufacturing scalability, and need for standardized quality control—while outlining future opportunities for RNA-loaded EV-based therapeutics.

8 January 2026 in Diseases
Verified
Journal Article
Open access
PDF file
AGAnastasia Ganina
Anastasia Ganina
ABAbay Baigenzhin
Abay Baigenzhin
ECElmira Chuvakova
Elmira Chuvakova
NYNaizabek Yerzhigit
Naizabek Yerzhigit
AZAnuar Zhunusov
Anuar Zhunusov
MAManarbek Askarov
Manarbek Askarov
Background: Chronically non-healing thoracic wounds after cardiac and non-cardiac thoracotomy, including cases when coronary artery bypass grafting (CABG) is performed, represent a great clinical challenge. It is often that a conservative treatment of the wounds does not provide effective regeneration of the damaged tissues. It is especially critical in patients with infected wounds, in patients owning a systemic infection, and in elderly people. Methods: The article presents a case report of successful treatment of a 63-year-old man with refractory chronic osteomyelitis of the sternum and mediastinitis four years after CABG, complicated by COVID-19 at the time of reconstructive surgery. Due to the low effectiveness of conservative treatment methods, a two-stage approach was applied: radical surgical wound debridement followed by infiltration of the wound with allogenic mesenchymal stromal cells (MSCs) of Wharton’s jelly (WJ-MSCs). Results: This double-stage therapy successfully modulated the inflammatory environment and stimulated granulation, facilitating final thoracoplasty and osteosynthesis. The patient achieved complete healing of the sternum, demonstrating benefits of WJ-MSCs in treating conservative treatment-resistant infections in the surgical wound. Conclusions: The advantages of using perinatal mesenchymal stem cells, with WJ-MSCs as a type of this class of MSCs, were demonstrated in treating chronically infected sternal surgical wounds. We also compared their regenerative properties to other stem cell types like bone marrow MSCs.

12 November 2025 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Open access
PDF file
ДБД.к. Берикбол
Д.к. Берикбол
AGAnastasia Ganina
Anastasia Ganina
YSY. Shayakhmetov
Y. Shayakhmetov
АБА.д. Бримова
А.д. Бримова
DID. Idrissova
D. Idrissova
ДИД.н. Идрисова
Д.н. Идрисова
Relevance: Non-small cell lung cancer (NSCLC) is frequently diagnosed in men with associated myocardial pathologies. Radiation therapy is one of the treatment methods for NSCLC; however, in Kazakhstan, there are virtually no studies on the efficacy and safety of tomotherapy in cancer patients with cardiac pathologies. The study aimed to evaluate the clinical results of mono-tomotherapy in patients with NSCLC and concomitant cardiac pathologies at the International Oncology Center for Tomotherapy “UMIT” (Astana, Kazakhstan). Methods: The study included 201 men with NSCLC who underwent spiral mono-tomotherapy at UMIT between 2020 and 2024. Patients were divided into Group 1 (n=139) – patients without cardiac pathologies- and Group 2 (n=62) – patients with severe associated cardiac pathologies. The average course duration was 32 days, the average treatment duration was 15 minutes, OD, 5 days a week. Treatment efficacy was assessed 8-12 weeks after completion of the course using PET-CT and CT data. Results: Complete regression was more common in patients in Group 1, while disease progression was more common in patients in Group 2. Partial responses were more common in Group 1, and stabilization of the oncological process was more common in Group 2. In Group 2, the proportion of patients with positive dynamics was 49%; after accounting for the identified stabilization of the process, it was 84%. In Group 1, the one-year overall survival rate was 84%, and 74% for stages III and IV, respectively, with a median progression-free survival of 10.3 months. The two-year survival rate for stage III disease was 65%. In Group 2, the one-year overall survival rate was 76% and 63% for stages III and IV, respectively, with a median progression-free survival of 8.1 months and a two-year survival rate of 54% for stage III. No device malfunctions were observed in Group 2. Two patients undergoing coronary artery bypass grafting experienced decompensated heart failure requiring temporary hospitalization. Conclusion: Tomotherapy demonstrates high clinical efficacy in the treatment of NSCLC with severe comorbid cardiac disease, although overall survival and treatment efficacy were lower than in patients without cardiac disease. Our experience confirms the feasibility of a relatively safe treatment in such patients when a personalized approach, strict dosimetric control, and multidisciplinary monitoring are employed

30 September 2025 in Russian Open Medical Journal
Verified
Journal Article
Closed access
AGAnastasia Ganina
Anastasia Ganina
MDMarlen Doskali
Marlen Doskali
LZLina Zaripova
Lina Zaripova
MAManarbek Askarov
Manarbek Askarov
PMPerizat Muhamedzhanova
Perizat Muhamedzhanova
ABAbay Baigenzhin
Abay Baigenzhin
Lung cancer with a five-year survival rate of less than 20% is currently one of the most common malignancies worldwide. Cell-based immunotherapy showed promising results over the past two decades, but some patients still experience disease progression. Numerous studies identified the critical role of the tumor microenvironment in tumor progression, immune evasion, and treatment response. The dynamic interplay between the tumor and its surrounding microenvironment significantly influences both tumor behavior and the immune response. One of the critical components of this interplay is how essential nutrients and structural support are involved in tumor growth per se and cancer pathophysiology in general. A comprehensive understanding of the underlying mechanisms and molecular players critical to the tumor microenvironment is crucial to optimize immunotherapy strategies. This review examines key therapeutic targets in lung cancer, uncovering the complex interactions within the tumor microenvironment to enhance the efficacy of immunotherapy.